Vanda Pharmaceuticals (VNDA) Tops Q4 Views
Get Alerts VNDA Hot Sheet
Revenue Growth %: +77,502.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $53.04 million versus the consensus estimate of $51.7 million.
GUIDANCE:
2019 Financial Guidance
Vanda expects to achieve the following financial objectives in 2019:
Full Year 2019 Guidance | |
Combined net product sales from both HETLIOZ® and Fanapt® | $215 to $225 million |
HETLIOZ® net product sales | $137 to $143 million |
Fanapt® net product sales | $78 to $82 million |
Year-end 2019 Cash | Greater than $260 million |
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Stride Inc. (LRN) Tops Q3 EPS by 17c, provides guidance
- Equity Residential (EQR) Tops Q1 EPS by 44c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!